We are live on ! Find out more

CPRX

Catalyst Pharmaceutical

CPRX

Delisted

CPRX was delisted on the 14th of July, 2026.

99 hedge funds and large institutions have $169M invested in Catalyst Pharmaceutical in 2018 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 47 increasing their positions, 22 reducing their positions, and 15 closing their positions.

New

Increased

Maintained

Reduced

Closed

271% more call options, than puts

Call options by funds: $293K | Put options by funds: $79K

114% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 22

29% more capital invested

Capital invested by funds: $131M → $169M (+$38.4M)

1% more funds holding

Funds holding: 98 → 99 (+1)

7% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 15

0.54% less ownership

Funds ownership: 53.36% → 52.82% (-0.54%)

Holders

Holders Change

Holders Change %

+1.02%

% of All Funds

2.27%

Holding in Top 10

Holding in Top 10 Change

Holding in Top 10 Change %

% of All Funds

0.02%

New

Increased

Reduced

Closed

Calls

$293K

Puts

$79K

Net Calls

+$214K

Net Calls Change

+$232K

Top Buyers

1	AC Armistice Capital New York	+$5.16M
2	BlackRock New York	+$4.13M
3	SI Sofinnova Investments Menlo Park, California	+$3.95M
4	CCM Consonance Capital Management New York	+$3.19M
5	Morgan Stanley New York	+$1.69M

Top Sellers

1	GPP Great Point Partners Greenwich, Connecticut	-$6.44M
2	Renaissance Technologies New York	-$3.77M
3	EA Emerald Advisers Leola, Pennsylvania	-$3.22M
4	BBA Baker Bros. Advisors New York	-$2.3M
5	EMFAT Emerald Mutual Fund Advisers Trust Leola, Pennsylvania	-$2.24M

#	Name	Holding	Trade Value	Shares Change	Change in Stake
26	26 Prudential Financial Newark, New Jersey	$960K	+$407K	+134,200	+77%
27	PAM 27 Panagora Asset Management Boston, Massachusetts	$866K	+$676K	+222,885	+407%
28	28 Bank of New York Mellon New York	$858K	+$113K	+37,388	+16%
29	TCM 29 Tanaka Capital Management New York	$782K	-$17.9K	-5,910	-2%
30	RJFSA 30 Raymond James Financial Services Advisors St. Petersburg, Florida	$739K	–	–	–
31	SO 31 STRS Ohio Columbus, Ohio	$696K	–	–	–
32	32 Charles Schwab San Francisco, California	$651K	+$71.3K	+23,500	+13%
33	33 Squarepoint New York	$629K	+$221K	+72,950	+57%
34	34 Deutsche Bank Frankfurt Am Main Ge, Germany	$608K	-$1.73M	-568,963	-74%
35	TA 35 Teachers Advisors New York	$608K	+$90.3K	+29,762	+18%
36	36 Royal Bank of Canada Toronto, Ontario, Canada	$516K	+$413	+136	+0.1%
37	37 Acadian Asset Management Boston, Massachusetts	$476K	+$463K	+152,638	New
38	PVI 38 Pura Vida Investments New York	$468K	+$455K	+150,000	New
39	AA 39 ALPS Advisors Denver, Colorado	$465K	+$34.7K	+11,453	+8%
40	40 California State Teachers Retirement System (CalSTRS) West Sacramento, California	$461K	+$43.6K	+14,356	+11%
41	41 Renaissance Technologies New York	$457K	-$3.77M	-1,243,034	-89%
42	MWNA 42 Marshall Wace North America New York	$329K	+$320K	+105,345	New
43	43 RhumbLine Advisers Boston, Massachusetts	$283K	+$70.9K	+23,383	+35%
44	44 Lido Advisors Los Angeles, California	$273K	+$84.2K	+27,766	+46%
45	45 Two Sigma Advisers New York	$270K	+$61.6K	+20,300	+31%
46	BFM 46 Boothbay Fund Management New York	$263K	-$118K	-38,819	-32%
47	47 Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada	$242K	+$29.1K	+9,577	+14%
48	48 New York State Common Retirement Fund Albany, New York	$238K	+$3.64K	+1,200	+2%
49	AIG 49 American International Group New York	$196K	+$20.9K	+6,903	+12%
50	SAM 50 Silphium Asset Management London, United Kingdom	$176K	+$171K	+56,497	New

CPRX Hedge Fund Activity: Q2 2018 in Review

99 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q2 2018, worth a combined $169M — up 29% from $131M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new CPRX positions and 15 closed out — a net gain of 1 holder — while 47 added to existing stakes and 22 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $5.16M. The largest seller was Great Point Partners, exiting entirely with an estimated $6.44M sold.

99 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q2 2018, up from 98 in Q1 2018.
Funds reported $169M of Catalyst Pharmaceutical stock for Q2 2018, up 29% quarter-over-quarter.
16 funds opened new Catalyst Pharmaceutical positions in Q2 2018 and 15 closed out, a net change of +1 holder.
The largest Catalyst Pharmaceutical buyer in Q2 2018 was Armistice Capital, an estimated $5.16M added.
The largest Catalyst Pharmaceutical seller in Q2 2018 was Great Point Partners, an estimated $6.44M sold.

Based on aggregated 13F filings for Q2 2018.

Catalyst Pharmaceutical CPRX